|Bid||101.00 x 1100|
|Ask||102.00 x 1000|
|Day's Range||98.95 - 104.34|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2020 - Feb 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||206.93|
CARLSBAD, Calif., Dec. 07, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription.
GW Pharmaceuticals plc (NASDAQ:GWPH) shareholders might be concerned after seeing the share price drop 26% in the last...
LONDON and CARLSBAD, Calif., Dec. 05, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid.
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...
Cannabis stocks were slammed anew on Tuesday, after the U.S. Food and Drug Administration issued new guidance on CBD that included a stark warning that it can cause liver injury and other damage to the human body.
Canopy Growth Corp., the Canadian cannabis company that is the market leader thanks to a $4 billion investment from a major drinks company, will not be profitable on a per-share basis by fiscal 2022, MKM analyst Bill Kirk said Friday.
Cannabis stocks headed lower Tuesday after a Monday communication from the FDA, which sent warning letters to 13 companies for illegally selling products containing containing cannabidiol (CBD), violating the Federal Food, Drug, and Cosmetic Act. The 15 companies were warned for marketing CBD products for therapeutic uses in humans and/or animals as well as as dietary supplements. The FDA continues to maintain a strict stance on regulating the consumer CBD market, Bank of America Merrill Lynch analyst Christopher Carey said in his review of the dual communications from the FDA.
Number of questions regarding CBD’s safety and there are real risks that need to be considered,’ official says as pot stocks fall in after-hours trading
FDA Says CBD Can Hurt Your Liver Potentially speaking. Potentially, anything can hurt your liver, but that isn’t stopping the Food and Drug Administration from singling out cannabidiol (CBD), the nonpsychoactive cannabinoid generally recognized as safe by most people, but not officially so by the FDA. The compound is now sold in pharmacies including CVS […]The post Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries appeared first on Market Exclusive.
CARLSBAD, Calif., Nov. 22, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in.
Dr. Stephen Hahn, President Donald Trump’s nominee for commissioner of the Food and Drug Administration, on Wednesday told members of Congress he believes “aggressive action” is needed on vaping yet declined to say whether he supports a flavor ban.
After a brutal start to the month for cannabis investors, the ETF MANAGERS TR/TIERRA XP LATIN AME (NYSE: MJ ) has rallied 8.6% this week on the heels of a Canopy Growth Corp (NYSE: CGC ) upgrade by Bank ...
GW Pharmaceuticals PLC (NASDAQ: GWPH) announced two of its medicines have been recommended by the U.K.’s National Institute for Health and Care Excellence to receive routine reimbursement from the National Health Service. Epidiolex, known as Epidyolex in Europe, and Sativex were approved by the NHS for the treatment of epilepsy and multiple sclerosis, respectively.
New guidelines issued in the United Kingdom for the consumption and prescription of cannabis issued by the National Institute for Health Care and Excellence fell short of expectations, according to Cantor Fitzgerald. The guidelines are an example of the challenges that Canadian LPs and others could face in key European markets, analyst Pablo Zuanic said in a Tuesday note. This translates to only 8,000 to 9,000 patients out of a population of 500,000 who suffer from other types of epilepsy in the U.K., the analyst said.
GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day